Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Liabilities: 2019-2024

Historic Other Non-Current Liabilities for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $286,000.

  • BridgeBio Pharma's Other Non-Current Liabilities rose 80.11% to $679,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $679,000, marking a year-over-year increase of 80.11%. This contributed to the annual value of $286,000 for FY2024, which is 94.92% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Other Non-Current Liabilities of $286,000 as of FY2024, which was down 94.92% from $5.6 million recorded in FY2023.
  • Over the past 5 years, BridgeBio Pharma's Other Non-Current Liabilities peaked at $26.6 million during FY2022, and registered a low of $286,000 during FY2024.
  • In the last 3 years, BridgeBio Pharma's Other Non-Current Liabilities had a median value of $5.6 million in 2023 and averaged $10.9 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 169.92% in 2020, then slumped by 94.92% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Other Non-Current Liabilities (Yearly) stood at $9.5 million in 2020, then surged by 131.82% to $22.1 million in 2021, then climbed by 20.73% to $26.6 million in 2022, then plummeted by 78.85% to $5.6 million in 2023, then slumped by 94.92% to $286,000 in 2024.